WELBIO is an inter-university life sciences research institute based in Wallonia, Belgium. WELBIO aims at promoting scientific excellence in fundamental life sciences research and translating scientific achievements in medical, pharmaceutical and veterinary biotechnology applications.
In an article published in The Journal of Clinical Investigation, researchers at the University of Liege, co-directed by Fabrice Bureau, WELBIO investigator, have, for the first time, identified the existence of a sub–group of eosinophils called resident eosinophils which are present in the lungs of healthy individuals and which, unlike inflammatory eosinophils, play a regulatory and protective role while maintaining the balance of the immune system and preventing it from responding in an abnormal way such as observed during an asthma attack. The discovery of these specific eosinophils offers promising therapeutic and prophylactic opportunities for the treatment and prevention of asthma.
WELBIO is pleased to announce a “Bridge grant” has been awarded to Professor Pierre van der Bruggen, Principal Investigator at the de Duve Institute (Université Catholoque de Louvain). The WELBIO Bridge fund is intended for WELBIO investigators and designed to bridge the gap between early stage research and the valorisation of the research findings (patent application, technology transfer, applied research project).
In a study published in Nature, researchers led by Pr. Cédric Blanpain, MD/PhD, WELBIO investigator, and Professor at the Université Libre de Bruxelles, in collaboration with Pr. Benjamin D Simons, University of Cambridge,UK, demonstrated that the capacity of oncogene-expressing cells to induce tumor formation depends on the clonal dynamics of the cancer cell of origin.